Treat-to-Target is Feasible and Beneficial in Lupus
Treating patients with lupus until they reach specific health goals can reduce disease flares and prevent organ damage, according to a research team co-led by Dr. Eric F. Morand, who is a past recipient of the Distinguished Innovator Award from the Lupus Research Alliance.
This study is important because it provides specific standards that allow doctors to see how well lupus treatment is working and to predict the long-term prognosis for patients.
FDA Expedites Existing Drug for Lupus Nephritis
The LRA is pleased to share that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Gazyva® (obinutuzumab) for adults with lupus nephritis.
Breakthrough Therapy Designation aims to speed up the development and review of drugs that are intended to treat a serious condition when “preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).”
Gazyva® is an existing drug from the Roche Group that is approved by the FDA for treating certain types of cancer.
The Lupus Research Alliance is the world’s leading authority in lupus research thanks to your support. Please donate today.
 | 
